Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 8/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978339 | 0.91 | CYP4F2 (0.49) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL982179 | 0.90 | CYP4F2 (0.50) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL9947664 | 0.90 | CYP4F2 (0.48) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL1078144 | 0.84 | CYP4F2 (0.52) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL979073 | 0.84 | GPR119 (0.59) | CYP4F2CYP4A11GPR119 | |
| SCHEMBL978348 | 0.83 | CYP4F2 (0.54) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL981851 | 0.83 | GPR119 (0.60) | CYP4F2CYP4A11GPR119WNT3A | |
| Hydrochloric Acid SCHEMBL1080624 | 0.82 | CYP4F2 (0.53) | CYP4F2CYP4A11GPR119WNT3A | |
| SCHEMBL1092277 | 0.81 | GPR119 (0.60) | CYP4F2CYP4A11GPR119 | |
| SCHEMBL1092945 | 0.80 | GPR119 (0.53) | CYP4F2CYP4A11GPR119WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2454251-A1 | GPR119 AGONISTS | Eli Lilly and Company (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008663-A1 | GPR119 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | CYP4F2 1001/4885CYP4A11 510/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.